ADMA Biologics, Inc. (ADMA)
$10.31+1.28%Close
BUYRECOVERY · day 17
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $2.4B
- Beta
- 0.77
- P/E (TTM)
- 14.32
- Short % float
- 9.09%
- Days to cover
- 5.7
- SI change
- -14.9%
- 1W
- +1.28%
- 1M
- +12.80%
- vs SPY 1W
- +0.85%
- vs SPY 1M
- +10.74%
Industry peers
FMP comparable companies · ranked by market cap
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 74
- VALUE
- 38
- GROWTH
- 66
- GARP
- 92
- TYPE
- Growth Compounder (blended)
Composite of Value · Growth · GARP
ROIC23.8%
REV YoY-
ROE39.6%
EPS YoY-
ROA24.7%
GROSS65
OP42
NET33
[VALUATION]
P/E TTM14.32
P/E FWD12.37
SECTOR PE20.34
INDUSTRY PE13.84
P/B5.76
P/FCF-
EV/EBITDA10.55
EV/EBIT-
PEG0.67
FCF YIELD-
RISK
INT COV-
D/E49.94
ALTMAN Z-
CURR RATIO6.97
ND/EBITDA-
BETA0.77
Company news
FAQ
- What is LOPJLB’s current signal on ADMA?
- LOPJLB’s latest quantitative signal on ADMA Biologics, Inc. (ADMA) is BUY in a RECOVERY regime. Signals are updated daily.
- What market regime is ADMA in?
- ADMA Biologics, Inc. (ADMA) is currently classified in the RECOVERY HMM market regime on LOPJLB.
- What does ADMA Biologics, Inc. (ADMA) do?
- ADMA Biologics, Inc. functions as a biopharmaceutical company specializing in the development, manufacturing, and commercialization of advanced biologic therapies derived from blood plasma. These specialized products are engineered to address immune system disorders and infectious diseases, catering to markets across the United States and internationally. Their current product portfolio include…